950210 Stock Chart & Stats
₩5050.00
-₩10.00(-0.20%)
―
--
Day’s Range― - ―
52-Week Range₩4,940.00 - ₩14,120.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)26.03K
Market Cap
₩303.49B
Enterprise Value₩504.06B
Total Cash (Recent Filing)₩63.01B
Total Debt (Recent Filing)₩106.11B
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1541.66
Shares Outstanding60,096,153
10 Day Avg. Volume34,284
30 Day Avg. Volume26,031
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.89
Price to Sales (P/S)14.89
P/FCF Ratio-6.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Rapid Revenue GrowthRapid revenue expansion indicates that Prestige BioPharma is increasing commercial scale across its biologics activities. If supported by approvals and partner commercialization, this growing base can improve operating leverage and provide a stronger platform for future earnings.
Oncology Pipeline And ApprovalsRegulatory recognition for PBP1510 and European authorization for TUZNUE provide durable validation of the company’s oncology and biosimilar strategy. These milestones can expand addressable markets, support commercialization, and diversify future revenue beyond development-stage assets.
Moderate LeverageModerate and declining leverage gives the company a comparatively supportive balance-sheet foundation while it scales its pipeline. Lower debt relative to equity can preserve financial flexibility for development and commercialization, although profitability remains necessary to strengthen returns.
Bears Say
Persistent Cash BurnPersistent negative operating and free cash flow means the business is not yet funding operations internally. Continued reliance on external capital can increase financing risk, constrain strategic flexibility, and make execution more vulnerable if funding conditions become less favorable.
Unstable ProfitabilityThe return from a profitable 2025 to heavy losses in 2026 demonstrates that revenue growth has not translated into dependable economics. Negative gross profit suggests costs are ahead of sales, limiting earnings visibility and making sustainable returns dependent on improved scale and cost control.
Potential Equity DilutionExpanded authority to issue shares, rights offerings, and equity-linked instruments may help fund the company’s growth strategy, but it also creates a durable dilution risk. Additional issuance could reduce existing holders’ proportional ownership and increase dependence on capital markets.
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh News
950210 FAQ
What was Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s price range in the past 12 months?
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh lowest stock price was ₩4940.00 and its highest was ₩14120.00 in the past 12 months.
What is Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s market cap?
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s market cap is ₩303.49B.
When is Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s upcoming earnings report date?
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s upcoming earnings report date is Nov 26, 2026 which is in 28 days.
How were Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s earnings last quarter?
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh released its earnings results on Sep 22, 2026. The company reported -₩730.426 earnings per share for the quarter.
Is Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh overvalued?
According to Wall Street analysts Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s price is currently Undervalued.
Does Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh pay dividends?
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh does not currently pay dividends.
What is Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s EPS estimate?
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh have?
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh has 60,096,153 shares outstanding.
What happened to Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s price movement after its last earnings report?
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh reported an EPS of -₩730.426 in its last earnings report. Following the earnings report the stock price went up 0.687%.
Which hedge fund is a major shareholder of Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh?
Currently, no hedge funds are holding shares in KR:950210
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh
Established in 2015 and based in Singapore, Prestige BioPharma Limited operates as a biopharmaceutical enterprise. The company's activities encompass the research, development, and commercialization of biosimilars and novel antibody therapeutics, primarily targeting the Asia Pacific market. A significant focus for Prestige BioPharma is the creation of antibody-based treatments for critical conditions such as solid tumors, pancreatic cancer, breast cancer, gastric cancer, and arthritis. Furthermore, the firm is also advancing the development of vaccines for the COVID-19 virus.
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh (950210) Earnings & Revenues
Technical Analysis
Pharmicell Co., Ltd
―
GeneOne Life Science, Inc.
―
Bioneer Corporation
―
ToolGen Incorporated
―
SK bioscience Co.,Ltd.
―